Back to News
Jan 12, 2026 4:00 PM

Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial

On Saturday, Johnson & Johnson (NYSE:JNJ) shared new longer follow-up results from the Phase 1b/2 OrigAMI-1 study.

The trial is evaluating Rybrevant (amivantamab-vmjw) in combination with FOLFOX or FOLFIRI chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer.

The company said that encouraging anti-tumor activity, durable responses, and low rates of treatment-related discontinuations observed in this study support further investigation in ongoing Phase 3 studies in first- and second-line colorectal cancer.

Results were presented at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium.

Detailed Study Results

At a median follow-up of 16 months, amivantamab plus FOLFOX (n=20) or FOLFIRI (n=23) achieved a confirmed overall response rate (ORR) of ...